There is a fact about routine GI testing that almost nobody explains to patients, and it changes how you should hear the words “your colonoscopy was completely normal.”
Your digestive tract is roughly twenty-five feet long. A colonoscopy — the test most adults associate with a “full” GI exam — examines about five of those feet, entering from below. An upper endoscopy covers roughly two more from above. That leaves nearly eighteen feet of small intestine — the region responsible for absorbing your iron, your B12, and most of your nutrition — that neither test examines. Not because your gastroenterologist cut corners. Because no scope can physically reach it.
“Normal scopes” means “normal in the seven feet we could see.”
Millions of adults carry diagnoses that were made not by finding something, but by not finding it. Unexplained iron-deficiency anemia after clean scopes. Fatigue that tracks with a ferritin level that keeps drifting down. Chronic bloating, pain, or bowel changes filed under “IBS” once the colonoscopy came back clear.
Research on obscure GI bleeding — bleeding with no source found on standard scopes — attributes the majority of cases to the small bowel, most often tiny flat vascular lesions called angioectasias. These lesions sit flush against the intestinal wall. They are invisible to scopes that can’t reach them, frequently invisible to CT scans, and — critically — easy to miss even for the older generation of “pill cameras,” whose single forward-facing lens looks down the middle of the tunnel while flat lesions hide along the walls and behind folds.
Engineers in Silicon Valley approached the problem differently. Instead of one camera facing forward, they placed four high-resolution cameras around the capsule’s circumference — creating a complete 360° panoramic view that photographs the intestinal wall directly.
The result, the CapsoCam Plus®, is FDA-cleared and roughly the size of a large vitamin. It requires no sedation, no wires, no recorder vest, and no hospital. In a prospective, multicenter, randomized head-to-head trial against a standard forward-viewing capsule, the panoramic design identified 107 lesions versus 85 — roughly 29% more findings in the same patients. In published series, patients complete the study successfully from home at rates above 90%, and in preference research, 80% of patients chose the wire-free design over belt-and-recorder systems.
For the first time, examining the blind spot doesn’t require a hospital, a months-long referral chain, or a lost day of work. A physician-supervised study — swallowed at your own kitchen counter — can now visualize the entire small bowel, with every frame read by a board-certified gastroenterologist.
A physician-led program in North Texas — The Traverse Scan™ — has built direct access around exactly this. But — and this is the part that separates real medicine from a gadget — it does not start with the capsule.
Premier Regenerative Health’s program begins with a GI Intelligence Assessment: ferritin and a full iron panel, fecal calprotectin (the stool marker of intestinal inflammation), and a private telehealth review with a physician who examines your results, your symptoms, and your history — then tells you honestly whether the small bowel blind spot is worth examining in your case, or whether it isn’t. Every patient receives a written Small Bowel Risk Summary either way, and only clinically appropriate patients are offered the Traverse Scan itself.
It is, in other words, the opposite of being dismissed: a physician whose entire job in that visit is to take your “normal-but-not-normal” results seriously.